Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September
(Thomson Reuters ONE) -
Press Release
22 August 2017
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August
and September
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel, immune-priming cancer treatment against a variety of solid
tumors, today announced that Immunicum leadership will present the Company at
several upcoming investor and partnering conferences in August and September.
Swedish-American Life Science Summit 2017
Date: August 23 - 25, 2017
Presentation Time: August 25, 12:00 pm Central European Time
Venue: Nasdaq Stockholm, Tullvaktsvägen 15, Stockholm, Sweden
Pareto Securities' 8th Annual Healthcare Conference
Date: September 7, 2017
Presentation Time: 12:15 pm Central European Time
Venue: Conference 7A Strandvägen 7A Stockholm, Sweden
24th Annual NewsMakers in the Biotech Industry
Date: September 8, 2017
Presentation Time: 8:30 - 8:55 am Eastern Standard Time
Venue: Millennium Broadway Hotel & Conference Center, New York, NY
Rodman & Renshaw 19th Annual Global Investment Conference
Date: September 10 - 12, 2017
Presentation Time: September 11, 5:30 - 5:55 pm Eastern Standard Time
Venue: Lotte New York Palace Hotel, New York, NY
Nordic Life Science Days 2017
Date: September 12 - 14, 2017
Presentation Time: September 13, 10:40 am Central European Time
Venue: Malmömässan, Mässgatan 6, Hyllie, Malmö, Sweden
RedEye Cancer Immunotherapy "Special Event"
Date: September 21, 2017
Presentation Time: TBD - time will be posted on Immunicum website
Venue: Redeye, Mäster Samuelsgatan 42, 10 tr, Stockholm, Sweden
BioPharm America
Date: September 26 - 27, 2017
Presentation Time: TBD - time will be posted on Immunicum website
Venue: Sheraton Boston Hotel, Boston, MA
17th Annual Sachs Biotech in Europe Forum
Date: September 26 - 27, 2017
Presentation Time: September 27, 12:00 pm Central European Time
Venue: Congress Center Basel, Switzerland
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info(at)immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg(at)halvarsson.se
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer(at)macbiocom.com or smay(at)macbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the
development of allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the patient's own
immune system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the potential
to become a backbone component of modern cancer combination treatments in a
variety of solid tumor indications. Founded and based in Sweden, Immunicum is
publicly traded on the Nasdaq First North Premier. www.immunicum.com
-------------------------------------------------------------------------------
20170822_Immunicum_August and September Conferences_EN_Final:
http://hugin.info/171739/R/2128345/812839.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 557316
Anzahl Zeichen: 4353
contact information:
Town:
Gothenburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunicum AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
